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Abstract The Alzheimer’s Association’s Research Roundtable met in November 2016 to explore how best
to measure changes in cognition and function in the preclinical stage of Alzheimer’s disease. This
review will cover the tools and instruments currently available to identify populations for prevention
trials, and measure subtle disease progression in the earliest stages of Alzheimer’s disease, and will
include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints
for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer’s
Prevention Initiative Autosomal Dominant Alzheimer’s Disease Trial, the Alzheimer’s Prevention
Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s to
compare current approaches and tools that are being developed.
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1. Introduction
As knowledge of Alzheimer’s disease (AD) progression
improves, the field has recognized that it may be possible,
and perhaps necessary, to develop drugs that target early,
prodromal stages of the disease and move to secondary pre-
vention as a treatment strategy. To achieve regulatory
approval for such therapeutics, appropriate clinically rele-
vant endpoints are needed that enable detection of disease
progression and response to therapy in a population that is,
by definition, asymptomatic. On November 29 and 30,
2016, the Alzheimer’s Association Research Roundtable
convened academic, industry, and government scientists to
explore cognitive, functional, and biological endpoints that
will enable clinical trials to be conducted in the earliest, pre-
symptomatic stages of AD pathophysiology and discuss the
challenges that need to be overcome. A number of secondary
prevention trials are already underway, providing the forum
with preliminary information to guide future development.
2. Cognition across the age and disease continuum
2.1. Normal cognitive aging
Defining normal cognitive function in older adults is sur-
prisingly complicated due to variability in how and in whom
it is measured. For example, in a 2002 cross-sectional study
of 345 people between the ages of 20 and 92 years, Park et al.
showed that while test performance in many cognitive do-
mains—including reasoning, working memory, and pro-
cessing speed—declined over the lifespan, scores on tests
of vocabulary and world knowledge increased [1]. In addi-
tion, neuroimaging has revealed that, just as with physical
health, brain health declines along a continuum with age,
with progressive reductions in brain volume and white mat-
ter integrity [2]. In fact, age-related declines in cognitive
function are correlated with reductions in the volume and/
or thickness of brain structures and white matter integrity,
and poor cognition may serve as a proxy for the integrity
of brain structure. It also is assumed to serve as a correlate
for the ability to function in everyday life.
Besides measuring structural changes in the brain, it is
also possible to measure brain activity using functional
magnetic resonance imaging. Typically, cognitively
normal adults will show increased activity, particularly in
the frontal cortex, with age. Park et al. (2009) proposed
the Scaffolding Theory of Aging and Cognition to account
for this increased brain activity, which posits that age-
related neural degradation within brain structures can be
counterbalanced by “compensatory scaffolding” (i.e., the
engagement of additional neural circuits, neurogenesis,
and other active processes, resulting in some protection
from decline in cognitive function [2]). The Dallas Life-
span Brain Aging Study was developed to test this model,
and other large normative data sets, such as the Virginia
Cognitive Aging Project, Health and Retirement Study,
and Harvard Aging Brain Study (HABS), have provided
further data to describe how cognition changes over the
lifespan. In addition to documenting overall age-related de-
clines in cognitive performance, the HABS and Dallas
Lifespan Brain Aging studies have also measured the depo-
sition of amyloid, a hallmark protein of AD, in seemingly
healthy, cognitively normal adults and have shown a link
between early deposition and poorer scores on tests of
memory and other cognitive processes [3,4]. Amyloid
deposition is associated also with the apolipoprotein E
(APOE) ε4 genotype [5] and with greater decline in cogni-
tive function over time [6].
The methods for studying changes in cognition with age
are problematic. Cross-sectional designs are used in most
studies of the aging brain and may be confounded by
cohort differences and sampling issues. For example, in
1963, a 20-year-old performed better on tests of psy-
chomotor speed, executive function and language than a
20-year-old born in 1922 [7]. Hence, an age difference in
cognition between a 20-year-old and an 80-year-old could
be either due to decline with age or due to the fact that there
was already quite a difference between the two at the age
of 20 years. In addition, cohort effects on dementia inci-
dence were recently reported from the Einstein Aging
Study [8] suggesting that the adverse effects of brain aging
may be diminished in younger compared with older co-
horts. A related issue is that obtaining a cognitively normal
representative sample of older study participants is diffi-
cult. First, older individuals carry many comorbidities
that exclude large subsets of individuals from studies; sec-
ond, the remarkable ability to image neuropathology such
as amyloid and tau at early stages of deposition compli-
cates what we mean by “normal cognitive aging” [9].
Another complication in lifespan studies is that middle-
aged participants are difficult to recruit and often are rep-
resented by cohorts who differ in employment, education,
and socioeconomic status relative to both the younger and
older adult samples in a cross-sectional study. The alter-
native is a longitudinal cohort study (LCS) design. Often
considered the gold standard for tracking cognitive perfor-
mance over time, longitudinal testing may be confounded
by practice effects. However, a recent analysis indicates
that when practice effects are eliminated, age trends in lon-
gitudinal studies closely resemble those seen in cross-
sectional studies [10].
It is important to recognize that cognition is not a unitary
construct, consisting, instead, of a number of discrete do-
mains, such as, for example, attention,memory, and language,
to name a few. The accurate measurement of cognitive func-
tion requires careful sampling and an assessment of factors
that could affect cognition that are unrelated to a therapeutic
intervention (e.g., education, past testing, and other, myriad
variables, unique to the individual). Young and old adults
may rely on different cognitive operations or different se-
quences of operations to achieve optimal performance on an
identical task. For example, young adults may rely on speed
and working memory—abilities where they excel—to
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perform a complex task, whereas older adults may rely on
their cognitive strengths—experience and vocabulary—to
solve the same task [11,12].
Finally, the focus on everyday cognition (ECog) and
instrumental activities of daily living (IADL) as measure-
ments of cognitive ability has important advantages and dis-
advantages for measuring change. The advantage, of course,
is that itmore closely reflects how an individual is performing
in the real world. An effect on these measurements after an
intervention is therefore ecologically valid, and highly rele-
vant to patients and caregivers. However there are also signif-
icant disadvantages—that is, people differ greatly in the
types of everyday tasks they perform. For example, some
are relatively simple, such as remembering to collect eggs
in a farm daily at a specific time, while others are more com-
plex, such as overseeing a bank or dispatching a fleet of trucks
to transport materials across a country. Thus, a single scale of
daily living activitiesmay not be sensitive enough tomeasure
the outcome of an intervention in very early disease stages in
different individuals [13,14]. An alternative to using tests of
ECogmight be high-frequency assessments via cell phone or
tablet computer in the context of a person’s everyday envi-
ronment [15]. The drawback here, however, is that many
older adults have little experience with these devices and so
simpler technology (a regular telephone) may be considered
for those without more modern technology.
In summary, the measurement of cognition for purposes
of a clinical trial is a complex issue and should be tailored
to the subject population under study and the particular goals
of the project. It may be advisable to include some measures
that make a study comparable to others, by using instruments
such as the National Institute of Health (NIH) toolbox,
which was designed to serve as a common currency among
longitudinal and intervention studies [16,17].
2.2. Lessons learned from LCSs
Two population-based LCSs—the Religious Orders Study
and the Rush Memory and Aging Project—have collected
more than 20 years of clinical data frommore than 3000 older
persons who were cognitively normal for age at enrollment.
As of late 2016, approximately 650 of the participants have
dementia and approximately 850 have mild cognitive impair-
ment (MCI). Neuropathological data have now been obtained
frommore than 1200 postmortem brain autopsies. These data
show that most cognitive decline in older adults is due towell-
known pathologies, and that decline progresses most rapidly
in people who have a combination of AD, cerebrovascular,
and Lewy body disease pathology [18,19]. These studies
have also shown that different cognitive domains decline at
different rates depending on the type of pathology. For
example, markers of AD neuropathology were associated
with a decline in episodic memory, semantic memory, and
working memory [16].
Several other LCS such as the Alzheimer’s Disease Neuro-
imaging Initiative (ADNI), Mayo Clinic Study of Aging, and
the Australian Imaging, Biomarkers and Lifestyle Flagship
Study of Ageing (AIBL) have also collected data on partici-
pants in the preclinical stages of AD, defined as the presence
of one or more positive biomarkers of AD pathophysiology
and no symptoms of cognitive impairment. The AIBL study
is a prospective LCS of cognitive aging collecting and inte-
grating data from neuroimaging (amyloid positron emission
tomography [PET] imaging and magnetic resonance imaging
measuring hippocampal volume), biomarkers, lifestyle, as
well as clinical and neuropsychological measures. Eligible
volunteers, over the age of 60 years and fluent in English,
were classified into three groups: (1) individuals meeting
the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association, now known as the Alzheim-
er’s Association (NINCDA-ADRDA) criteria for AD [20],
(2) individuals meeting criteria for MCI [21,22], and (3)
elderly healthy controls (HC). The 6-year follow-up data
confirmed other studies that indicated a 20- to 30-year pro-
gression of brain amyloid b (Ab) accumulation before
dementia is diagnosed, after which accumulation begins to
plateau as dementia progresses [23]. Among amyloid-
positive participants, 28.6% progressed over 6 years
compared to 11.9% among amyloid-negative participants.
When age is taken into account, the decline accelerates; and
carriage of the APOE ε4 allele was also associated with an
accelerated rate of decline [24]. Cognitively normal subjects
in ADNI have also been tested with several cognitive mea-
sures, showing that elevated brain amyloid is associated
with decline in cognitive test scores, which, albeit, remain
within normal limits for age, in contrast to minimal decline
in scores in participants without brain amyloid [25].
2.3. Early changes in the AD continuum
Population-based studies of aging point to the difficulty
of distinguishing normal from pathological aging. A decline
in cognitive test scores within begins more than a decade
before dementia becomes apparent in persons destined to
become demented and proceeds in a continuous manner
over time [26,27]. Most standardized tests provide age-
corrected norms, and although decline may occur in an indi-
vidual, test scores may continue to remain within average
limits for age, masking the decline. Furthermore, a change
in test scores that does not render the individual abnormal
for age may correlate poorly with everyday functional abil-
ities. Thus, detecting cognitive change that is of clinical sig-
nificance in the early preclinical stages of AD is challenging.
The role of cognitive reserve further complicates the matter.
One strategy to assess these issues is to determine “per-
sonally relevant” indices of cognitive decline. One strategy
to highlight personally relevant decline is to correct test
scores for the individual’s peak prior level of cognitive ab-
ility as estimated by reading vocabulary scores [28].
Revised diagnostic criteria define preclinical disease by
the presence of cerebral amyloid deposits, assessed using
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amyloid PET imaging or cerebrospinal fluid (CSF) bio-
markers [29–31], yet studies correlating these findings to
even sensitive measures of cognition show small changes
and substantial variance [32–34]. A recent analysis from
the Mayo Clinic Study of Aging showed that elevated
amyloid is associated with poorer cognition across
multiple domains, with the greatest change in global
cognition, attention, and memory, but not language [35].
The evidence is substantial that b-amyloidosis, with its
201 year preclinical time course and its lack of
neuroanatomical-cognitive domain relationships, is not the
proximate driver of cognitive decline. Instead, evidence of
neurodegeneration—assessed by hippocampal atrophy, levels
of CSF tau, or tau PET imaging, fludeoxyglucose PET hypo-
metabolism, or magnetic resonance-derived measures of
cortical volume or thickness—is also required [36–39]
before cognitive impact is obvious. Fig. 1 illustrates a hypo-
thetical interaction of amyloid and tau, proposed by Sperling
et al. in 2014 [6]. Still unknown is whether these represent
separate assaults or if one drives the other. But to the extent
that these various measures are only modestly correlated
(e.g., from [40]: [41–46]), it is likely that these biomarkers
represent at least partially independent aspects of the AD
pathophysiologic process.
APOE ε4 seems to accelerate amyloid-related decline,
suggesting possible synergistic effects of amyloid and
APOE ε4 [47]. In addition, deterioration of brain function
as a biological consequence of aging may lead to cognitive
decline. Subjective cognitive concerns also appear to be
associated with preclinical AD, particularly in APOE ε4 car-
riers, although as the disease progresses, affected individuals
become less aware of their declining cognition, a condition
known as anosognosia [48,49].
3. Cognitive composites and batteries as endpoints in
prevention trials
Several AD prevention trials are currently underway, using
different endpoints as primary outcome measures. These end-
points include time-to-event endpoints, such as time to the
first diagnosis of MCI due to AD and continuous measures
of cognition. To assess cognition, these studies have all
selected cognitive measures most sensitive in the defined
study population, combining them into a “battery” or “com-
posite” measure (Table 1). Composites may be theoretically
or statistically derived or both.
3.1. TOMMORROW
TOMMORROW is a study designed to test the efficacy of
low-dose pioglitazone in delaying the onset of MCI or AD
and to qualify a biomarker risk algorithm for identifying
cognitively normal older adults at risk for developing MCI
due to AD within 5 years, based on TOMM40 rs10524523
genotype, APOE genotype, and age. This study uses a
time-to-event design in combination with a linguistically
and culturally valid neuropsychological battery of tests,
which captures the transition from normal to early-stage
symptomatic disease. The battery enables operationalization
of the National Institute on Aging/Alzheimer’s Association
core clinical criteria for MCI due to AD [30] by requiring,
fulfillment of the clinical criteria across two consecutive ex-
aminations at least 6 months apart, consisting of decline in
the Clinical Dementia Rating scale score from 0.0 to 0.5
plus either (1) a decline from baseline on at least one of
the two memory tests in the battery with performance falling
at least 21.5 standard deviation below the normative mean
after age adjustment or (2) a decline from baseline on a
memory test and one other test in a domain other than mem-
ory with performance falling at least 21.3 standard devia-
tion below the mean. Other potential causes must be ruled
out as the proximal cause of cognitive impairment and
each assessment is adjudicated by a panel of clinical demen-
tia experts.
The cognitive test battery includes at least two tests in
each of five domains: Episodic Memory, Executive Func-
tion, Language, Visuospatial Processing, and Attention.
The English version has been translated, culturally adapted,
validated, and normed for ages 65 to 88 years in German,
Italian, and Russian and shown to be psychometrically sound
and sensitive in early AD [50]. The battery is designed to
mirror a memory evaluation that would be conducted in clin-
ical practice with cognitively healthy adults at risk for devel-
oping MCI. Including two tests for each domain guards
against judgments of impairment based on single spuriously
low scores. In addition, by having dual measures for each
domain, an overall global cognitive composite score can
be calculated, which incorporates all domains, even in the
setting of missing test scores. This is important for purposes
of measuring continuous changes in cognition in healthy
adults, including signs of cognitive decline or symptomatic
improvements.
3.2. Alzheimer’s prevention initiative
The Alzheimer’s Prevention Initiative (API) had two clin-
ical trials underway at the time of the Roundtable meeting;
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Fig. 1. Hypothetical interaction of amyloid and tau in preclinical AD. Ab-
breviations: AD, Alzheimer’s disease; MTL, medial temporal lobe. From
reference [6].
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one, a treatment and biomarker development trial in people
with autosomal dominant AD (ADAD)mutation and the other
in APOE ε4 homozygotes (the API Generation Study). Both
trials are enrolling cognitively normal individuals close to
their estimated age of clinical onset. The API ADAD study
uses a cognitive composite as the primary endpoint, while
the Generation Study uses dual primary endpoints, the API
Preclinical Composite, and time to diagnosis of MCI or de-
mentia due to AD. The compounds being tested also differ.
TheADAD trial is testing Roche’s crenezumab, a monoclonal
antibody that targets Ab; while the Generation trial will test
two compounds: CNP520 (developed by Novartis and Am-
gen), an inhibitor of BACE1, the b-secretase enzyme that
cleaves the amyloid precursor protein at an early step in the
formation of amyloid plaques [51]; and CAD106, an active
immunotherapy that targets Ab. Participants are randomized
to either treatment or its placebo.
The API ADAD Composite was empirically derived us-
ing a data set from the world’s largest kindred of PSEN1
E280A mutation carriers and noncarriers [52]. Separately,
the API Preclinical Composite was empirically derived
from three cohorts of unimpaired older adults (Rush Alz-
heimer’s Disease Center’s Religious Orders Study, Memory
and Aging Project, and Minority Aging Research Study)
who progressed or did not progress to AD, thereby control-
ling for cognitive decline associated with normal aging
[53]. The API Preclinical Composite will be used for the
API Generation Study and other prevention trials. In each
case, the goal was to find the most sensitive combination
of test items to detect and track cognitive decline
Table 1
Comparison of cognitive composites used in prevention trials
Domain Test TOMM API ADAD APCC PACC PACC-A4
Global functioning and
mental status
MMSE
Attention WAIS-III Digit Span, forward
Trails A
Perceptual speed Symbol digit modalities 2
Executive function Trails B
WAIS-III Digit Span,
backward
WAIS-R Digit Symbol
Substitution Test
Ravens Progressive Matrices
(subset)
Orientation MMSE orientation to place
MMSE orientation to time
Language Multilingual Naming Test
Semantic fluency (animals)
Lexical/phonemic fluency
(FAS)
Boston Naming Test 1
Visuospatial Clock drawing
Copy of BVMT-R figures
Judgment of line orientation 3
CERAD–constructional
praxis
Ravens Progressive Matrices
(subset)
Episodic memory CVLT
Brief Visuospatial Memory
Test
CERAD Word List–delayed
recall
Logical Memory–delayed
recall
FCSRT
Paragraph Recall
Abbreviations: APCC, API Preclinical Composite; TOMM, TOMMORROW trial; API ADAD, The Alzheimer’s Prevention Initiative–Autosomal Dominant
Alzheimer’s Disease; PACC, Preclinical Alzheimer’s Cognitive Composite; A4, Anti-Amyloid treatment in Asymptomatic Alzheimer’s; MMSE, Mini-Mental
State Examination; WAIS-III, Wechsler Adult Intelligence Scale–Third Edition; WAIS-R, Wechsler Adult Intelligence Scale–Revised; BVMT-R, Brief Visuo-
spatial Memory Test–Revised; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CVLT, California Verbal Learning Test–Second Edition;
FCSRT, Free and Cued Selective Reminding Test; RBANS, Repeatable Battery for Neuropsychological Status.
NOTE. Green color5 used in this composite; 15 replaced byMultilingual Naming Test (MiNT); 25 replaced by RBANS coding; 35 replaced by RBANS
line orientation; 4 5 replaced by RBANS list recall; 5 5 replaced by RBANS story recall; 6 5 adapted WAIS-R Digit Symbol Substitution Test.
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associated with preclinical AD and evaluate the efficacy of
preclinical treatment.
3.3. PACC-HABS and A4
The Alzheimer’s Disease Cooperative Study Preclinical
Alzheimer’s Cognitive Composite (ADCS-PACC) is a retro-
spectively and theoretically derived composite measure de-
signed to track subtle cognitive decline in clinically normal
older adults and in a slightly modified form (PACC-A4) to
be used as a primary outcome measure for trials conducted
in the preclinical stage of AD, including the Anti-Amyloid
Treatment in Asymptomatic Alzheimer’s (A4) study [25,54].
The composite, comprising tests of episodic memory,
executive function, and global cognition, was derived
retrospectively using three data sets: theADCS–Prevention In-
strument (ADCS-PI) study, ADNI, and AIBL. The ADCS-PI
studied cognitively normal individuals over the age of 75 years
for four years with the goal of developing measures for trials
earlier in the AD course. This study did not include measures
of amyloid level (CSF or PET) but used the presence of at least
1 APOE ε4 allele as a predictor of decline. More importantly,
theADCS-PI included the Free andCuedSelective Reminding
Test, Wechsler Adult Intelligence Scale–Revised Digit Sym-
bol Substitution test, New York Paragraph recall instead of
the Wechsler Memory Scale–Revised Logical Memory and
the Modified Mini-Mental State Examination instead of the
Mini-Mental State Examination (MMSE) that were used to
derive this version of the ADCS-PACC. In comparison,
ADNI included the ADAS-Cog Word List instead of the
Free and Cued Selective Reminding Test, Wechsler Memory
Scale–Revised Logical Memory Story A, Wechsler Adult In-
telligence Scale–Revised Digit Symbol Substitution test, and
MMSE to derive that ADCS-PACC. For AIBL, the ADCS-
PACC was derived from the California Verbal Learning
Test–Second Edition list A, Wechsler Adult Intelligence
Scale–Third Edition Coding, Wechsler Memory Scale–Third
Edition Logical Memory Story A, and MMSE. The PACC
used in A4 (PACC-A4) differed from all of these three, in
that, it comprises an alternative version of the Free and Cued
Selective Reminding Test (not the one used in ADCS-PI),
Wechsler Adult Intelligence Scale–Third Edition Coding
(a shortened version 90 versus the validated 120-second
version), nonvalidated Logical Memory Stories, and the
MMSE. Data presented at the Research Roundtable demon-
strated how the PACC performs over time in a preclinical pop-
ulation, that is, older adults enrolled in the HABS who have
evidence of amyloid deposition.
A revised version of PACC is under development and vali-
dation. The revised version of PACC has been developed
retrospectively from data from preclinical AD in the ADNI,
AIBL, Mayo Clinic Study of Aging, and Washington Univer-
sity cohorts at approximately 3-, 4-, and 5-year follow-up
points [55,56]. Lasso Regression models have been applied
uniformly to the slopes of performance over time for
individual neuropsychological tests in clinically normal
adults from each of the different cohorts. Using this
approach, and restricting the modeling to tests most readily
applied in global trials (i.e., minimizing language/cultural
translation and expert test administration and scoring
requirements), the resultant revised version of PACC
assesses the same cognitive domains as the ADCS-PACC
and achieves equivalent or modestly better separation of
Ab1 and Ab2 groups over time periods used in clinical trials
of preclinical AD.
3.4. European Prevention of Alzheimer’s Disease
The European Prevention of Alzheimer’s Disease
(EPAD) program recently published a consensus statement
recommending cognitive measures comprising the EPAD
Neuropsychological Evaluation for planned large-scale
drug trials in preclinical AD [57]. This work was predicated
on a published literature review, examining existing LCS of
nondemented cohorts that went on to develop incident de-
mentia, as well as data from neuroimaging studies to deter-
mine the temporal order and brain biomarker correlates of
specific cognitive functions [58]. The results of the literature
review indicated that there are particular neuropsychological
tests and cognitive domains for which subtle cognitive
changes are detectable before a clinical diagnosis of MCI,
and that with which significant differences between cogni-
tively normal and preclinical populations can be detected
in within 5 years of diagnosis. The tests therefore recom-
mended by the EPAD Clinical and Cognitive Outcomes Sci-
entific Advisory Group are shown in Table 2. The EPAD
LCS includes the EPAD Neuropsychological Evaluation,
Table 2
EPAD-ENE: Measures and cognitive domains
Cognitive domains Measures
Primary
Verbal episodic memory List learning and story memory
(RBANS)
Visual episodic memory Figure recall (RBANS)
Visuospatial/constructional Figure copy and line orientation
(RBANS)
Language Picture naming (RBANS)
Attention/executive functioning Semantic fluency (RBANS)
Digit span (RBANS)
Coding (RBANS)
Secondary
Working memory Dot counting (NIH examiner/
toolbox)
Choice reaction time and set-
shifting
Flanker (NIH examiner/toolbox)
Paired associate learning Name/face pairs (NIH examiner/
toolbox)
Exploratory
Allocentric space Four mountains task
Egocentric space Supermarket trolley virtual reality
Abbreviations: EPAD-ENE, EPAD Neuropsychological Evaluation;
RBANS, Repeatable Battery for Neuropsychological Status; NIH, National
Institute of Health.
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and the measures contained within are denoted as primary,
secondary, and exploratory. For EPAD, the endpoint desig-
nated as primary is the total scale index score, an overall
composite of the Repeatable Battery for Neuropsychological
Status, which the Scientific Advisory Group deemed to be
well validated and having a favorable likelihood of regulato-
ry acceptance. Secondary measures are those with empirical
support for their use, but requiring either additional valida-
tion by a second independent study (i.e., EPAD LCS), vali-
dated alternative forms, or additional normative data.
Exploratory measures are those with initial empirical evi-
dence supporting their use, but requiring two well-
designed studies (i.e., EPAD LCS and EPAD) Proof of
Concept with concordant findings to further validate these
measures. The Repeatable Battery for Neuropsychological
Status will serve as the criterion measure for the psychomet-
ric validation of these secondary and exploratory measures.
Overall, based on the literature, the selected EPAD Neu-
ropsychological Evaluation reflects the Scientific Advisory
Group’s conclusion that many trials and studies-to-date
have tended to focus on episodic memory functions of the
hippocampus, while neglecting its other roles in cognition,
such as spatial navigation and spatial memory; and that
novel tests may be needed to target other brain regions where
both tau and Ab pathologies co-occur in early-stage disease,
such as the entorhinal cortex, precuneus, and retrosplenial
cortex. Finally, it should be noted that for the EPAD LCS
and Proof of Concept studies, the Repeatable Battery for
Neuropsychological Status Total Scale Index score serves
at the primary endpoint for regulatory purposes.
4. Functional measures
Although functional decline is thought to occur only after
cognitive decline, studies suggest that subtle functional
decline occurs even in cognitively normal individuals who
later progress to MCI or AD [13,59–61]. Indeed, the
presence of mild or subtle functional changes in persons
who meet criteria for MCI [30] has raised some conceptual
concerns about how to define the boundaries of MCI. More-
over, everyday function is important to patients and families
because functional impairment results in loss of autonomy
and independence and is related to quality of life. Among
the activities that have been explored in functional assess-
ments, in early AD are complex everyday activities, such
as financial capacity, driving, computer usage, and other
everyday activities such as shopping. Various methods
have been developed to carefully quantify functional
changes among older adults. Such methods include
performance-based measures, in which older adults are
directly observed and rated on their ability to perform
various functional tasks. Questionnaire-based measures of
everyday function have also been developed, in which a
wide range of everyday activities is assessed, and these ques-
tionnaires can be completed by the patient (self-report) and/
or the study partner (informant report). Recent advances in
both types of tools have included a focus on measuring
very early changes that occur in MCI and “Pre-MCI.”
The University of California San Diego Performance-
Based Skills Assessment (UPSA) was developed as a
performance-based measure to assess performance across
four domains: communication, comprehension and plan-
ning, transportation and mobility, and finance. In a study
of cognitively normal elders as well as patients with amnes-
tic MCI and mild-to-moderate AD, UPSA scores demon-
strated stepwise impairment across the disease continuum.
The effect size in distinguishing HC from MCI was greater
with the UPSA compared the Alzheimer’s Disease Cooper-
ative Study—Activities of Daily Living Inventory [62]. A
short form with only the communication and comprehension
domains has been shown to correlate well with the long form
and to have acceptable sensitivity and specificity for distin-
guishing between HC, individuals withMCI, and individuals
with AD dementia [63]. Impairments in episodic memory
and semantic memory have been shown to predict perfor-
mance on the UPSA, further supporting the idea that func-
tional and cognitive domains are systematically related
[64,65]. Overall, what remains to be determined is how the
UPSA will perform in populations tested earlier in the
disease course than those previously studied. There are
also a number of other performance-based functional assess-
ments such as the Harvard Automated Phone Task or the
Financial Capacity Instrument, which have also shown
promise in detecting early, clinically meaningful changes
in preclinical AD, although such tasks need to control for
prior experience [66,67].
Alternatives to performance-based measures include both
informant-reported and patient-reported ratings of everyday
function. The ECog scale is one such assessment tool, which
independently queries the patient and an informant about
everyday functional abilities across six domains: memory,
language, visual perception, planning, organization, and
divided attention [68]. Informant-based ratings on the ECog
have been shown to be associated with objective measures
of disease status (e.g., neuropsychological function, structural
imaging measures of brain atrophy, and PET/CSF bio-
markers), although self-reports might also have sensitivity
in early disease stages [69,70]. Informant-rated ECog scores
are also strongly associated with the risk of progression
from MCI to dementia [71].
The relative sensitivity and predictive utility of informant
versus patient ratings of functioning remains unclear. Farias
et al. have shown that in amixed diagnostic sample, informant
report is consistently more strongly associated with disease
biomarkers than self-report [69]. During the meeting, Farias
presented data showing that when comparing informant and
self-ratings on the ECog to predict risk of progression from
MCI to dementia, self-report is a significant but a weaker pre-
dictor than the informant report (Table 3). In contrast, in a new
study recently published by the same group [72], self-rated
ECog was an equally if not better predictor than informant
report in terms of progression from normal cognition to
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MCI. Such findings suggest that changes in self-reported
everyday function may be useful early in the disease process
but that, as cognitive impairment advances, the informant’s
report may offer a more robust assessment. Among older
adults who live alone, informant report may not be possible.
Limitations of self-report are anosognosia (i.e., frank denial
and/or unawareness of one’s own deficits) and factors such
as anxiety or depression that may increase the tendency to
report cognitive symptoms [73].
Deficits in IADL are typically assessed using rating scales
administered to patients or informants. In a systematic review
of IADL scales, Sikkes et al concluded that all 12 scales re-
viewed fell short in important basic psychometric properties
[14] such as reliability, validity, and responsiveness to change.
Testing these properties is a basic assumption for adequate
measurements of both cognition and function. A second sys-
tematic review in 2016 concluded that there was limited evi-
dence for content and construct validity [74]. In addition, the
review noted that patients were confused by complex ques-
tions, which highlights the importance of involving the target
population in the development of such scales.
The Amsterdam IADL Questionnaire was designed to
correct some of the deficiencies of other IADL question-
naires [75]. The research team started by asking patients
and caregivers what activities they thought were relevant
and then involved clinicians and researchers to generate
IADL-appropriate questions that could be completed on a
computer by the study partner. This approach led to a range
of everyday activities, including cooking, finances, and
everyday technology use [75]. The Amsterdam IADL Ques-
tionnaire has been shown to be valid and reliable. In addi-
tion, it was shown to correlate longitudinally with
cognitive decline, which underlines the ability to detect
changes over time [76]. A short version was recently devel-
oped [77] and shown to be reliable and valid across the dis-
ease spectrum. That is, patients had increasing difficulties
with IADL along the disease spectrum. Notably, the short
version was able to detect IADL difficulties even in preclin-
ical AD when compared to HC, supporting the inclusion of
more complex IADL tasks to improve sensitivity to cogni-
tive decline [77]. Cross-cultural adaptations of the Amster-
dam IADL Questionnaire have been developed for several
countries, and others are currently being developed.
In sum, both performance-based measures and
questionnaire-based assessments of functional activities
have an added value to cognitive measurements. The best
approach may be to include both types of functional out-
comes in clinical trials if at all practical. While older func-
tional instruments were designed for use with individuals
who already had dementia, new instruments have been spe-
cifically developed to be sensitive to early functional
changes that predate a dementia diagnosis. Continued
advancement of functional tools might consider the merits
of including items that measure the use of technology in
daily life to assess early change. In addition, with the diver-
sity of older adults in the United States increasing, functional
tools need to be shown to be culturally relevant to a wide
range of older adults.
5. Biomarkers as predictors of clinical change in
preclinical AD
The National Institute on Aging-Alzheimer’s Associa-
tion Preclinical Workgroup proposed a conceptual frame-
work for preclinical AD in 2011. In the 2011 framework,
cognitive functioning in the preclinical state was defined
only when both amyloid and neurodegeneration bio-
markers were abnormal. However, abnormal cognition
was left undefined when only one or none of the
biomarker classes was abnormal. While the 2011 Work-
group’s efforts represented a novel approach to relating
cognition to biomarkers in the preclinical state, work in
the past 6 years has required a major revision of the strat-
egy to relate biomarkers to cognition. For example, the
need to integrate tau PET imaging into the biomarker
framework and the recognition that there was a sizable
group, dubbed Suspected Non-Alzheimer Pathology not
accounted for [78], has led the Alzheimer’s Association
and the National Institute on Aging to convene a new
workgroup to develop a more flexible and inclusive
framework (cite Website version). Despite the inevitable
limitations that appeared in ground-breaking efforts of
the 2011 preclinical framework, there was one very clear
and consistent finding that emerged. Those persons who
were considered cognitively normal and who had both
abnormally elevated amyloid levels and abnormal levels
of a neurodegeneration biomarker have the worst cogni-
tive outcomes compared to all of the other biomarker
combination groups [79].
6. Is it possible to detect a clinically meaningful change
in preclinical AD?
At least eight preclinical AD prevention trials are
currently underway: A4 [54], the two API trials [80], a third
Table 3
Patient- versus informant-reported everyday function predicting MCI to
dementia conversion using E-Cog
Independent variable
Incident
dementia–patient
Incident
dementia–informant
HR (95% CI) HR (95% CI)
Everyday planning 1.7 (1.1–2.6)* 3.0 (2.2–4.1)*
Everyday memory 1.7 (1.3–2.4)* 3.0 (2.3–3.8)*
Everyday visuospatial 1.9 (1.2–3.0)* 2.7 (1.9–3.6)*
Everyday language 1.3 (0.8–1.9) 2.5 (1.8–3.5)*
Everyday organization 1.5 (1.05–2.2)* 2.6 (2.1–3.3)
Everyday divided attention 1.2 (0.8–1.6) 2.3 (1.8–2.9)*
ECog total score 1.8 (1.2–2.8)* 4.2 (3.0–5.8)*
Abbreviations: CI, Confidence interval; E-Cog, everyday cognition;MCI,
mild cognitive impairment; HR, hazard ratio.
*P value , .05.
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API trial sponsored by Novartis, and Amgen in heterozygote
E4 carriers (generation 2), the Janssen EARLY trial in
asymptomatic individuals with cerebral amyloid burden,
the Dominantly Inherited Alzheimer’s Network Trial [81],
TOMMORROW [82], and EPAD. Each of the groups plan-
ning these trials has wrestled with the question of how to
detect a clinically meaningful change in individuals who
are, by definition, cognitively and clinically normal. On
the one hand, population-based studies have detected subtle
cognitive changes in verbal fluency, learning, and recall
among individuals in the preclinical stage, and prospective
LCSs indicate that a decline in global cognition can be de-
tected in people at risk for AD [9,27]. Focus groups
conducted by the Patient-Reported Outcome Consortium
also suggest that persons in the preclinical stages of AD
notice problems (also referred to as subjective complaints
or concerns) in memory, language, attention, comprehen-
sion, processing speed, task performance, and interpersonal
function [83]. While declining cognitive function is not spe-
cific for AD, is heterogeneous, and is modified by age, edu-
cation, and comorbid diseases, it remains the best surrogate
for disease progression.
Composite measures have been proposed as a means of
better demonstrating clinical meaningfulness by using a
broader range of measures sensitive to a heterogeneous set
of symptoms and signs. For example, cognitive and func-
tional measures can be combined [84]. However, composites
have the potential to dilute some effects and thereby reduce
the ability to capture treatment effects. Different trials are
likely to require different measures, including combinations
of functional, cognitive, and biomarker assessments that are
sensitive at different points along the disease spectrum. Tria-
lists will also need to address the feasibility of administering
novel functional measures consistently across multiple cen-
ters.
Regulators are also grappling with identifying acceptable
endpoints for preclinical trials and harmonizing their guid-
ance across countries. The U.S. Food and Drug Administra-
tion issued a draft guidance document in 2013 on developing
drugs for early-stage AD [50] and is now working to update
that document. The European Medicines Agency has
released similar guidelines [85], and the two agencies are
working together to align. Health Canada generally follows
the Food and Drug Administration guidelines. Both the Food
and Drug Administration and European Medicines Agency
guidelines emphasize the importance of incorporating the
patient voice in developing acceptable measures that are
clinically meaningful.
7. Conclusions
The effort to prevent Alzheimer’s disease is still in early
stages of developing measures sensitive to preclinical dis-
ease. While a number of cognitive composites and func-
tional measures have shown some promise, it remains to
be seen whether existing tests have adequate sensitivity or
if new tests are required. There are also concerns about the
feasibility of certain measures in secondary prevention
studies that are likely to be large and lengthy. Repeated neu-
ropsychological testing raises concerns about learning ef-
fects and participant burden. However, properly designed
clinical trials could leverage and maximize practice effects
during the prescreening period, which would potentially in-
crease power to detect an interventional effect during the
trial and/or decrease the needed sample size. Alternatively,
it may be beneficial to reduce the amount of time spent on
testing by measuring fewer constructs but measuring them
more accurately. At some point, it will also be critical to
link change on cognitive and functional composites to clin-
ically meaningful outcomes, such as the duration of delay to
the onset of a diagnosis of MCI or dementia or to delay in
functional decline.
Heterogeneity of disease presents challenges in the
design of clinical trials, yet is a reality and, thus, must be ac-
counted for in trials. Thus, for example, some individuals
with AD may have more prominent visuospatial deficits in
early stages, while others may have more prominent amnesia
or aphasia [86]. This will mean developingmeasures capable
of capturing the heterogeneity of clinical or cognitive change
and the effect of a treatment on that change. Moreover,
increased efforts are needed to obtain study participants
representative of all ages, races, and ethnicities and of
different educational and socioeconomic levels.
Roundtable participants also called for increased research
to improve understanding of the course of cognition and
function from normal to impaired, including increased in-
vestment in large-scale, multisite studies of normal aging
that involve repeated neuropsychological and functional
testing of large groups. Continued investment in computer-
ized tools, such as the NIH toolbox [16], could help achieve
this goal through the use of more standardizedmeasures with
enhanced sensitivity to subtle cognitive changes. The NIH
toolbox also offers measures of noncognitive domains,
such as emotion, motor and sensory functions, which may
expand the scope of variables that could lead to earlier detec-
tion. For example, visual, olfactory, and motor changes have
been associated with increased risk of progression from a
state of normal aging to MCI and dementia [87–95]. In
addition, there is a need for a lingua franca of what
constitutes benefit to enable alignment of researchers,
clinicians, patients, regulators, payers, and policy makers
to move forward in developing preventive treatments. A
case has been made that public and private interests are
currently well aligned. It is an ideal time for the field to
coalesce on what constitutes a treatment benefit in
preclinical AD [96].
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RESEARCH IN CONTEXT
1. Systematic review: This review summarizes the pre-
sentations made at the November 2016 Research
Roundtable meeting. Each presenter reviewed the
literature of recent work in their specific topic areas
within the overall area of measuring Alzheimer’s dis-
ease progression in the preclinical stage.
2. Interpretation: The information covered in this
article summarizes, in the view of industry drug de-
velopers, the areas of work that need to be addressed
in research to achieve success in the development of
Alzheimer’s disease therapeutics to stop or slow pro-
gression at the earliest stages of disease.
3. Future directions: Guidelines are presented to direct
future efforts in the measurement of preclinical Alz-
heimer’s disease in individuals who are biomarker
positive for the disease.
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